BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8944421)

  • 1. Thrombin receptor-related hemostatic defect after cardiopulmonary bypass.
    Ferraris VA; Ferraris SP; Reich H; Rodriguez E; Huang M; Gupta A; Bennett JA; Andersen TT; Fenton JW
    Semin Thromb Hemost; 1996; 22(4):351-6. PubMed ID: 8944421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
    Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet dysfunction after normothermic cardiopulmonary bypass in children: effect of high-dose aprotinin.
    Flaujac C; Pouard P; Boutouyrie P; Emmerich J; Bachelot-Loza C; Lasne D
    Thromb Haemost; 2007 Aug; 98(2):385-91. PubMed ID: 17721621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
    Velik-Salchner C; Maier S; Innerhofer P; Kolbitsch C; Streif W; Mittermayr M; Praxmarer M; Fries D
    Anesth Analg; 2009 Jun; 108(6):1747-54. PubMed ID: 19448196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study.
    Chung A; Wildhirt SM; Wang S; Koshal A; Radomski MW
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):782-90. PubMed ID: 15821644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin receptor-activating peptide releases arachidonic acid from human platelets: a comparison with thrombin and trypsin.
    McNicol A; Robson CA
    J Pharmacol Exp Ther; 1997 May; 281(2):861-7. PubMed ID: 9152395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides.
    Connolly TM; Condra C; Feng DM; Cook JJ; Stranieri MT; Reilly CF; Nutt RF; Gould RJ
    Thromb Haemost; 1994 Oct; 72(4):627-33. PubMed ID: 7878643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reinfusion of autologous platelet-rich plasma improves hemostasis after cardiopulmonary bypass].
    Yamamoto K
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Aug; 40(8):1203-12. PubMed ID: 1402162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The platelet thrombin receptor and postoperative bleeding.
    Ferraris VA; Ferraris SP; Singh A; Fuhr W; Koppel D; McKenna D; Rodriguez E; Reich H
    Ann Thorac Surg; 1998 Feb; 65(2):352-8. PubMed ID: 9485228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
    Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
    Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
    van Oeveren W; Harder MP; Roozendaal KJ; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of autologous platelet-rich plasma (PRP) in cardiac surgery].
    Okamura T; Koh E; Yokoyama S
    Kyobu Geka; 2001 May; 54(5):397-400. PubMed ID: 11357304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
    Day JR; Haskard DO; Taylor KM; Landis RC
    Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
    Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin influences human platelet behavior in cardiac surgery with or without cardiopulmonary bypass.
    Laga S; Bollen H; Arnout J; Hoylaerts M; Meyns B
    Artif Organs; 2005 Jul; 29(7):541-6. PubMed ID: 15982282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of platelet reactivity in clopidogrel-treated subjects.
    Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
    J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.